cbdMD, Inc. Reschedules Earnings Release and Conference Call
cbdMD, Inc. (NYSE: YCBD) has postponed its Q4 and fiscal year 2024 financial results release and conference call from December 17 to December 18, 2024. The company cited the need for additional time to complete its year-end reporting process. The financial results will be released after market close on December 18, followed by a conference call at 4:20 p.m. Eastern Standard Time. The company expects to file its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, on the same day.
cbdMD, Inc. (NYSE: YCBD) ha rinviato la pubblicazione dei risultati finanziari del quarto trimestre e dell'anno fiscale 2024 dalla data precedentemente prevista del 17 dicembre al 18 dicembre 2024. L'azienda ha giustificato la decisione con la necessità di ulteriore tempo per completare il processo di rendicontazione di fine anno. I risultati finanziari verranno pubblicati dopo la chiusura del mercato il 18 dicembre, seguiti da una conferenza telefonica alle 16:20 ora standard orientale. L’azienda prevede di presentare il suo Rapporto Annuale sul Modulo 10-K per l'anno fiscale conclusosi il 30 settembre 2024, nella medesima giornata.
cbdMD, Inc. (NYSE: YCBD) ha pospuesto la publicación de sus resultados financieros para el cuarto trimestre y el año fiscal 2024 de la fecha original del 17 de diciembre al 18 de diciembre de 2024. La compañía citó la necesidad de tiempo adicional para completar su proceso de informes de fin de año. Los resultados financieros se publicarán después del cierre del mercado el 18 de diciembre, seguidos de una conferencia telefónica a las 4:20 p.m. Hora Estándar del Este. La empresa espera presentar su Informe Anual en el Formulario 10-K para el año fiscal que terminó el 30 de septiembre de 2024, el mismo día.
cbdMD, Inc. (NYSE: YCBD)는 2024 회계연도 4분기 재무 결과 발표 및 컨퍼런스 콜을 원래 예정된 12월 17일에서 12월 18일로 연기했습니다. 회사는 연말 보고 프로세스를 완료하기 위해 추가 시간이 필요하다고 밝혔습니다. 재무 결과는 12월 18일 시장 마감 후 발표되며, 이어서 동부 표준시 기준 오후 4시 20분에 컨퍼런스 콜이 진행됩니다. 회사는 2024년 9월 30일 종료된 회계연도에 대한 10-K 양식 연례 보고서를 같은 날 제출할 예정입니다.
cbdMD, Inc. (NYSE: YCBD) a reporté la publication de ses résultats financiers pour le quatrième trimestre et l'année fiscale 2024 de la date initialement prévue du 17 décembre au 18 décembre 2024. L'entreprise a cité le besoin de temps supplémentaire pour compléter son processus de reporting de fin d'année. Les résultats financiers seront publiés après la fermeture du marché le 18 décembre, suivis d'une conférence téléphonique à 16h20, heure normale de l'Est. L'entreprise prévoit de soumettre son Rapport Annuel sur le Formulaire 10-K pour l'exercice clos le 30 septembre 2024, le même jour.
cbdMD, Inc. (NYSE: YCBD) hat die Veröffentlichung der finanziellen Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 vom ursprünglich geplanten 17. Dezember auf den 18. Dezember 2024 verschoben. Das Unternehmen gab an, zusätzliche Zeit für den Abschlussbericht zu benötigen. Die finanziellen Ergebnisse werden nach Marktschluss am 18. Dezember veröffentlicht, gefolgt von einer Telefonkonferenz um 16:20 Uhr Eastern Standard Time. Das Unternehmen erwartet, am selben Tag seinen Jahresbericht auf Formular 10-K für das am 30. September 2024 endende Geschäftsjahr einzureichen.
- None.
- Delay in financial reporting indicates potential internal reporting complexities
- Last-minute postponement of earnings release may raise investor concerns about financial statement preparation
Charlotte, North Carolina--(Newsfile Corp. - December 17, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), today announced that it has postponed the release of its financial results and conference call related to the fourth quarter and fiscal year ended September 30, 2024, which had previously been scheduled for December 17, 2024. cbdMD currently expects to issue its fourth quarter and fiscal year 2024 financial results after market close on Wednesday, December 18, 2024. The Company is delaying the release of financial results and the conference call because it needs additional time to complete its year-end reporting process. The Company currently expects to hold its conference call, on Wednesday, December 18, 2024, at 4:20 p.m. Eastern Standard Time. The Company also currently expects to file its Annual Report on Form 10-K for the fiscal year ended September 30, 2024 on December 18, 2024.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport® products, as well as our new Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD sleep aids and CBD drink mixes and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxlabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, continued cost reductions, potential need for additional working capital, regaining compliance with NYSE American continued listing standards, continued listing on the NYSE American, future profitability, development and sales of new products, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 as filed with the Securities and Exchange Commission (the "SEC") and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
1 THC-free is defined as below the level of detection using validated scientific analytical methods.
Contact Information:
cbdMD, Inc.
Ronan Kennedy, CEO
Phone: +1 (704) 445-3064 email: IR@cbdmd.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234222
FAQ
When will YCBD release its Q4 and FY 2024 earnings?
Why did YCBD postpone its December 17 earnings release?
When is YCBD's rescheduled earnings conference call?
When will YCBD file its Annual Report Form 10-K for FY 2024?
